Ustekinumab for rapid treatment of nail psoriasis

Archives of Dermatology

Volumn 146, Issue 11, 2010, Pages 1315-1316

  Rallis, Efstathios ^a   Kintzoglou, Stephanos ^a   Verros, Constantinos ^b  

^a Veterans Administration Hospital NIMTS   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; ETANERCEPT; USTEKINUMAB;

ADULT; ARTICLE; CASE REPORT; FOLLOW UP; HUMAN; MALE; NAIL DISEASE; ONYCHOLYSIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; RECURRENT DISEASE; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; NAIL DISEASES; PSORIASIS;

EID: 78349273658     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.332     Document Type: Article

References (5)

1. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009;13(suppl 2):S102-S106.
2. Griffiths CE, Strober BE, van de Kerkhof P, et al; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118-128.
3. Leonardi CL, Kimball AB, Papp KA, et al; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665- 1674.
4. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20(1):60-67.
5. Rich P, Langley R, Guzzo C, et al. Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial. Poster presented at the 17th Congress of European Academy of Dermatology and Venereology; September 17-21, 2008; Paris, France.